A debt-to-equity ratio of 0.01 and current ratio of 19.85 in 2026Q3 indicate minimal leverage, although the roughly $500M equity build may partly reflect non-recurring license recognition and an accumulated deficit of -$84.0M persists.
Protagonist Therapeutics, Inc. (PTGX) balance sheet — 12-year assets, liabilities & shareholders' equity history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 | Dec'17 | Dec'16 | Dec'15 | Dec'14 |
|---|
| Total Current Assets | 1.1B | 577.57M | 591.64M | 355.58M | 243.08M | 340.74M | 315.61M | 145.31M | 137.5M | 150.95M | 83.24M | 14.21M | 9.91M |
| Cash & Short-Term Investments | 800.06M | 567.36M | 418.91M | 341.62M | 237.35M | 326.9M | 305.81M | 133.02M | 128.85M | 144M | 77.6M | 11.92M | 9.32M |
| Cash Only | 498.3M | 128.39M | 97.25M | 186.73M | 125.74M | 123.67M | 117.36M | 33.01M | 82.23M | 106.03M | 21.08M | 4.05M | 9.32M |
| Short-Term Investments | 301.77M | 438.97M | 321.66M | 154.89M | 111.61M | 203.24M | 188.45M | 100.01M | 46.62M | 37.97M | 56.52M | 7.87M | 0 |
| Accounts Receivable | 286.9M | 4.5M | 168.49M | 10.33M | 52K | 5.33M | 3.82M | 6.75M | 4.59M | 1.82M | 2.24M | 715K | 523K |
| Days Sales Outstanding | 59.86 | 35.66 | 141.56 | 62.85 | 0.71 | 71.15 | 48.72 | 10.67K | 54.14 | 33.04 | - | - | - |
| Inventory | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.14M | -8.75M | -7.65M | 0 | 10K |
| Days Inventory Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Other Current Assets | 10.13M | 0 | 0 | 0 | 0 | 0 | 10K | 754K | -205K | 10.24M | 8.16M | 315K | 56K |
| Total Non-Current Assets | 45.49M | 92.32M | 153.08M | 2.37M | 4.85M | 6.96M | 8.86M | 9.61M | 1.97M | 12.79M | 10.75M | 639K | 415K |
| Property, Plant & Equipment | 9.82M | 11.69M | 12.61M | 2.15M | 4.63M | 6.73M | 6.41M | 7.72M | 861K | 879K | 562K | 609K | 415K |
| Fixed Asset Turnover | 61.08x | 3.94x | 34.46x | 27.92x | 5.75x | 4.06x | 4.46x | 0.03x | 35.92x | 22.82x | - | - | - |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long-Term Investments | 252.91M | 78.92M | 140.25M | 0 | 0 | 0 | 2M | 0 | 450K | 11.46M | 10.15M | 30K | 0 |
| Other Non-Current Assets | 1.12M | 0 | 225K | 225K | 225K | 225K | 450K | 450K | 450K | 450K | 34K | 0 | 0 |
| Total Assets | 1.15B | 669.89M | 744.73M | 357.95M | 247.93M | 347.69M | 324.47M | 154.92M | 139.47M | 163.73M | 93.99M | 14.85M | 10.33M |
| Asset Turnover | 0.65x | 0.07x | 0.58x | 0.17x | 0.11x | 0.08x | 0.09x | 0.00x | 0.22x | 0.12x | - | - | - |
| Asset Growth % | 70.67% | -10.05% | 108.05% | 44.38% | -28.69% | 7.16% | 109.45% | 11.07% | -14.82% | 74.2% | 533.14% | 43.74% | - |
| Total Current Liabilities | 55.46M | 45.44M | 47.4M | 21.27M | 31.18M | 44.02M | 40.24M | 35.41M | 26.16M | 42.55M | 6.43M | 3.13M | 1.35M |
| Accounts Payable | 5.92M | 5.34M | 1.61M | 772K | 3.64M | 1.6M | 3.08M | 2.79M | 5.71M | 1.26M | 1.16M | 1.25M | 349K |
| Days Payables Outstanding | 1.4K | 1.59K | - | - | - | - | - | - | - | - | 1.34K | 1.84K | - |
| Short-Term Debt | 0 | 2.28M | 510K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Current) | 41.8M | 9.55M | 18.89M | 0 | 69K | 2.5M | 17.21M | 19M | 8.22M | 31.75M | 0 | 0 | 0 |
| Other Current Liabilities | 4.79M | 15.51M | 12.62M | 6.79M | 4.97M | 7.13M | 6.41M | 4.64M | 9.5M | 6.83M | 120K | 149K | 0 |
| Current Ratio | 19.85x | 12.71x | 12.48x | 16.71x | 7.80x | 7.74x | 7.84x | 4.10x | 5.26x | 3.55x | 12.94x | 4.54x | 7.34x |
| Quick Ratio | 19.85x | 12.71x | 12.48x | 16.71x | 7.80x | 7.74x | 7.84x | 4.10x | 5.17x | 3.75x | 14.13x | 4.54x | 7.34x |
| Cash Conversion Cycle | -1.34K | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Non-Current Liabilities | 6.18M | 9.74M | 22.03M | 0 | 1.14M | 3.66M | 4.62M | 39.55M | 799K | 547K | 0 | 2.12M | 1.02M |
| Long-Term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 9.79M | 0 | 0 | 0 | 0 | 0 |
| Capital Lease Obligations | 28.47M | 8.04M | 10.36M | 0 | 1.14M | 3.66M | 4.5M | 5.96M | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 1.71M | 1.71M | 0 | 221K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Liabilities | 0 | 0 | 11.68M | -221K | 0 | 0 | 121K | 0 | 799K | 547K | 0 | 2.12M | 1.02M |
| Total Liabilities | 61.64M | 55.19M | 69.43M | 21.27M | 32.32M | 47.67M | 44.86M | 74.95M | 26.96M | 43.1M | 6.43M | 5.25M | 2.37M |
| Total Debt | 8.63M | 10.32M | 10.87M | 1.14M | 3.66M | 5.86M | 5.96M | 17.01M | 0 | 0 | 0 | 0 | 0 |
| Net Debt | -489.67M | -118.07M | -86.38M | -185.59M | -122.09M | -117.81M | -111.4M | -15.99M | -82.23M | -106.03M | -21.08M | -4.05M | -9.32M |
| Debt / Equity | 0.01x | 0.02x | 0.02x | 0.00x | 0.02x | 0.02x | 0.02x | 0.21x | - | - | - | - | - |
| Debt / EBITDA | 0.03x | - | 0.04x | - | - | - | - | - | - | - | - | - | - |
| Net Debt / EBITDA | -1.47x | - | -0.34x | - | - | - | - | - | - | - | - | - | - |
| Interest Coverage | - | - | - | - | - | - | -107.89x | -459.82x | - | - | - | - | - |
| Total Equity | 1.08B | 614.71M | 675.29M | 336.68M | 215.61M | 300.02M | 279.61M | 79.96M | -140.47M | -101.55M | -64.59M | 9.6M | 7.96M |
| Equity Growth % | 80.22% | -8.97% | 100.58% | 56.15% | -28.14% | 7.3% | 249.66% | 156.92% | -38.33% | -57.22% | -773.12% | 20.63% | - |
| Book Value per Share | 15.12 | 9.67 | 10.38 | 5.93 | 4.40 | 6.48 | 8.13 | 3.09 | -6.28 | -5.74 | -9.93 | 1.63 | 1.35 |
| Total Shareholders' Equity | 1.08B | 614.71M | 675.29M | 336.68M | 215.61M | 300.02M | 279.61M | 79.96M | -140.47M | -101.55M | -64.59M | 9.6M | 7.96M |
| Common Stock | 1K | 1K | 1K | 1K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Retained Earnings | -84.02M | -470.67M | -340.52M | -615.71M | -536.75M | -409.36M | -283.81M | -217.66M | -140.47M | -101.55M | -64.59M | -27.42M | -12.56M |
| Treasury Stock | -5.79M | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -1.29M | 641K | -82K | -105K | -359K | -299K | 28K | -221K | -233K | -6K | -245K | -102K | -100K |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying PTGX stock.
As of 2025, Protagonist Therapeutics, Inc. (PTGX) had total assets of $669.9M including $577.6M in current assets.
Protagonist Therapeutics, Inc. (PTGX) carries total debt of $10.3M, offset by $567.4M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Protagonist Therapeutics, Inc. (PTGX) has total shareholders' equity (book value) of $614.7M ($9.67 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Protagonist Therapeutics, Inc. (PTGX) reported a current ratio of 12.71x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.
Key Metrics
Top Statement Risk
Milestone-dependent cash and revenue
Metrics are mathematically derived from official filings.
Cash Build Driven by Partner Milestones
Based on reported figures, PTGX's cash position rose from $97.2M in 2024Q4 to $498.3M in 2026Q3, a build that appears to rest on episodic partnership receipts rather than recurring operating inflows.
The step-up in total assets from roughly $670M to $1.1B over the last three quarters suggests the balance sheet is strengthening in headline terms. However, the timing of the increase lines up with milestone recognition, which may not repeat on a predictable schedule. Investors should monitor whether cash holds up in quarters without large partner payments.
Liquidity Comfortable but Partner-Dependent
According to the reported balance sheets, PTGX's current ratio of 19.85 in 2026Q3 and cash of $498.3M provide a wide near-term buffer against an operating loss profile that has persisted across the period.
A current ratio this elevated indicates that short-term obligations are minimal relative to liquid assets, which supports near-term solvency. The buffer is nonetheless sensitive to the pace of partner milestone receipts, since quarterly cash swings of more than $300M in recent periods imply that underlying burn is being masked. Investors should treat the liquidity position as adequate but contingent on continued partner execution.
Negligible Leverage Preserves Flexibility
As reported in the balance sheets, PTGX carried $8.6M of total debt against $1.1B of equity in 2026Q3, leaving a debt-to-equity ratio of 0.01 that presents minimal refinancing pressure.
Leverage is effectively immaterial, suggesting the company has funded its programs through equity and collaboration income rather than borrowing. This preserves strategic flexibility and removes debt service as a constraint on cash flow. The more relevant balance sheet pressure is operating burn, not financing obligations.
Accumulated Deficit Persists Despite Profit Quarter
Based on reported figures, PTGX's retained earnings moved from -$470.7M in 2025Q4 to -$84.0M in 2026Q3, a shift driven largely by a single quarter of $220.0M net income rather than sustained profitability.
The improvement in retained earnings narrows but does not eliminate the accumulated deficit, which remains negative across all ten reported quarters. Because the equity gain is concentrated in one period, it likely reflects non-recurring milestone recognition rather than a durable earnings base. Investors should be cautious about extrapolating the equity recovery.
Milestone Accounting Flatters the Headline Balance Sheet
The strongest counterpoint is that PTGX's 2026Q3 equity jump of roughly $500M may reflect non-recurring license recognition, as trailing revenue near $46.0M sits far below the $274.4M reported in that single quarter.
A balance sheet that appears to have strengthened sharply may be distorted by a lumpy revenue event that flows through deferred revenue and retained earnings simultaneously. The reported 89% year-over-year revenue decline and persistent operating losses suggest the underlying cost base has not shrunk. Investors should monitor whether deferred revenue unwinds in future quarters and whether cash declines once milestone inflows stop.